New Alzheimer's Drugs: Are They a Turning Point?
The 麻豆社's Medical Editor Fergus Walsh has been looking into how the trials are going and investigating whether patients may soon get access to these drugs on the NHS.
For decades there was little or no progress in efforts to treat Alzheimer's Disease. Then two drugs came along in close succession, promising a new way forward for some patients. Lecanemab and donanemab slow down the early stages of the disease - which is the most common form of dementia. The drugs represent a step forward because they target one of the causes of Alzheimer's, rather than treating the symptoms. However, their effectiveness depends on early diagnosis - and very few people have the specialist scans or investigations which would be needed. For 5 Questions On, the 麻豆社's Medical Editor Fergus Walsh has been looking into how the trials are going -- and investigating whether patients may soon get access to these drugs on the NHS.
